Loading clinical trials...

Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis | Clinical Trials | Clareo Health

COMPLETED

Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis

A Multicenter, Prospective and Retrospective, Long-Term Observational Study of AVONEX® and Rebif® to Determine the Efficacy, Tolerability, and Safety in Subjects With Relapsing Multiple Sclerosis (MS)

NCT00599274•Biogen

View on ClinicalTrials.gov

Summary

The purpose of this study is to find out if weekly Avonex works as well as three times a week Rebif in subjects with relapsing multiple sclerosis.

Detailed Description

This is a Phase 4, multicenter, prospective and retrospective, long-term observational study of Avonex® and Rebif® to determine the efficacy, tolerability, and safety in subjects with relapsing MS.

Eligibility

Age

18 - 50 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Must have been receiving AVONEX® or Rebif®.
•Must have a confirmed diagnosis of relapsing-remitting MS using the Poser criteria.
•Must have experienced at least 2 relapses within the 3 year period prior to the initiation of treatment.
•Must have an EDSS score of 0.0 to 5.5, inclusive.

Exclusion Criteria

•History of severe allergic or anaphylactic reaction or hypersensitivity to human albumin, to any interferon, or to other components of the drug formulation.
•History of poorly controlled hypertension and/or other clinically significant major disease.
•History of uncontrolled seizures within the 3 months prior to enrollment.
•History of suicidal ideation or an episode of severe depression within the 3 months prior to enrollment.
•Serious local infection or systemic infection within 8 weeks prior to enrollment.
•Treatment with certain other agents to treat MS symptoms or underlying disease.
•Treatment with any investigational product
•Previous participation in this study.

Locations (11)

Research Site

Los Angeles, California, United States

Research Site

Walnut Creek, California, United States

Research Site

Shreveport, Louisiana, United States

Research Site

Worcester, Massachusetts, United States

Research Site

Charlotte, North Carolina, United States

Research Site

Columbus, Ohio, United States

Research Site

Edmonds, Washington, United States

Research Site

Milwaukee, Wisconsin, United States

Coordinating Research Site

Woodville, Australia

Coordinating Research Site

Linz, Austria

Key Dates

Start Date

August 1, 2002

Completion Date

May 1, 2003

Last Updated

January 27, 2010

Enrollment

136

ACTUAL participants

Conditions

Multiple Sclerosis

Interventions

Interferon beta-1a

DRUG

Interferon beta-1a

DRUG

Intermittent Hypoxia in Persons With Multiple Sclerosis

NCT06276634

Multiple SclerosisMultiple Sclerosis-Relapsing-Remitting+1 more

View study

RECRUITINGPHASE3

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

NCT07225504

Secondary Progressive Multiple Sclerosis (SPMS)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 27, 2010Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis

Inclusion Criteria

Exclusion Criteria

Intermittent Hypoxia in Persons With Multiple Sclerosis

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

Factorial Optimization Trial to Test Cognitive Behavioral Therapy Components for Multiple Sclerosis Fatigue

Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

Cognitive Performance, Sleep Disturbances and Fatigue in Multiple Sclerosis

Wearable Focal Vibration Therapy on Upper Extremity Function of People With Multiple Sclerosis: A Pilot Study